Polyglutamic Acid for Suppressing Blood GIP Concentration
Solution Overview
Problem
Current agents for suppressing blood GIP concentration and preventing obesity are insufficient in terms of safety and effectiveness, as they either fail to adequately inhibit GIP function or have adverse effects on digestion and insulin resistance.
Innovation Solution
Polyglutamic acids are used as active ingredients to suppress elevation of blood GIP concentration, effectively preventing or improving obesity by administering them in various forms, including oral liquid preparations, to inhibit GIP secretion and absorption.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If BMPP or pyrazolopyrimidine compounds are used to inhibit GIP function, then obesity suppression is achieved, but safety and effectiveness are insufficient
Solution Approach 1:
The patent changes the chemical structure parameters from BMPP/pyrazolopyrimidine compounds to polyglutamic acid, a biocompatible polymer. This parameter change maintains GIP suppression effectiveness while improving safety by using a naturally occurring, biodegradable material with favorable pharmacokinetic properties.
Solution Approach 2:
The patent employs polyglutamic acid, which is rapidly degraded by proteases in the gastrointestinal tract into glutamic acid. This short-lived action pattern provides transient GIP suppression during the meal period without long-term accumulation, improving safety while maintaining effectiveness during the critical postprandial period.
2Reliability
If guar gum or similar substances are used to suppress GIP secretion, then some suppression effect is achieved, but the suppression is insufficient
Solution Approach 1:
The patent changes the molecular parameters from guar gum (complex polysaccharide) to polyglutamic acid (polypeptide). This structural parameter change enables direct interaction with GIP secretion mechanisms in K-cells, achieving superior suppression efficiency compared to the indirect effects of guar gum.
Solution Approach 2:
The patent applies polyglutamic acid before or during meal intake to preemptively suppress GIP secretion. This preliminary action prevents the postprandial GIP surge before it occurs, achieving more effective suppression compared to substances that act after GIP secretion has already been triggered.
3Reliability
If GIP function is inhibited to prevent obesity, then obesity risk is reduced, but digestion may be adversely affected
Solution Approach 1:
The patent employs periodic administration of polyglutamic acid timed with meal intake. This periodic action provides GIP suppression only during postprandial periods when obesity risk is highest, while allowing normal GIP function and digestion during fasting periods, thus preventing adverse effects on digestion.
Solution Approach 2:
The patent uses polyglutamic acid's rapid degradation property to limit GIP suppression to the brief postprandial period. The substance is degraded into harmless glutamic acid within hours, ensuring temporary obesity prevention without long-term interference with digestive hormone regulation and meal processing.
Data Source
AI summary
An agent for suppressing elevation of blood GIP concentration and an agent for preventing or improving obesity, each of which contains a polyglutamic acid as an active ingredient.